Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Diagnostics Oncology, Neurology, Biochemistry and molecular biology

From Neurobiology to Prostate Cancer Pathology

Metastatic prostate cancer is incurable – symptoms can only be managed – and there’s currently no way to predict when or if the disease will metastasize (1). To that end, researchers at King’s College London dug into the mechanisms behind prostate cancer – using knowledge gained in neurobiology – and discovered that the drebrin/EB3 pathway appears to play a role in prostate cancer’s invasiveness (1). Knockdown of either protein’s in vitro expression decreased the ability of the cancer cells to invade the prostrate stroma, while over-expression had the opposite effect. To find out if the pathway could be used as a therapeutic target or a biomarker for progression to metastasis, we speak with Philip Gordon-Weeks, lead investigator and professor of developmental neurobiology at King’s College London.

What do your findings mean for diagnosis and prognosis?

We haven’t cured prostate cancer, but I think we’ve taken a big step in the right direction. A key clinical issue in prostate cancer is predicting which prostate tumors will become metastatic. Evaluating the drebrin/EB3 pathway might help clinicians stratify patients by distinguishing between benign and malignant prostate cancer. However, I don’t think this would be done in isolation – one would want to examine a panel of prognosis predictive biomarkers.

The drebrin/EB3 pathway might also be a suitable target for pharmaceutical disruption. In our paper, we described using a drug (BTP2) that targets drebrin to disrupt prostate cancer cell invasion as a proof-of principle.

How does a professor of developmental biology end up working on prostate cancer?

Well, we actually discovered the drebrin/EB3 pathway while working on the embryonic development of the nervous system. We found that it enabled embryonic neurons to respond to homing signals in the embryo that helped them to build neuronal circuits. One step in this process involves the migration of new born neurons from their birthplace in the embryonic nervous system to the final position they will occupy in the adult. The event has similarities with cancer cell invasion and metastasis – both involve homing signals and re-organization of the cytoskeleton – and so we wondered whether cancer cells might use the same cellular machinery as neurons to do this.

When we started working on prostate cancer, I thought that we would be on a one-way-street – simply applying all the conceptual insights, reagents and tools that we had worked on in our developmental neurobiology studies to investigate prostate cancer cell invasion. But we also made several unexpected discoveries about the drebrin/EB3 pathway in prostate cancer cells that encouraged us to go back and look again at developing neurons – so we were on a two-way-street after all!

What were the major challenges you had to overcome?

An experimental hurdle for us was trying to mimic the in vivo situation in a tissue culture dish so that we could more easily study cancer cell invasion. This meant setting up 3D cultures with concentration gradients of homing signals. We chose the chemokine CXCL12 as a signal because there is good experimental evidence that it is involved in stimulating prostate cancer cells to invade the prostate stroma and to metastasize to bone (2). We also wanted to test the role of the drebrin/EB3 pathway in metastasis in a pre-clinical in vivo model, but at the time there were none that mimicked bone metastasis.

What’s next?

We are about to apply to the UK’s Medical Research Council for support to continue our work, including exploiting a newly described pre-clinical mouse model of prostate cancer metastasis to test the role of the drebrin/EB3 pathway. These are conceptually simple experiments, but very powerful. We will edit out the drebrin/EB3 pathway in human prostate cancer cell lines using CRISPR/Cas-9, and orthotopically transplant the cells into the prostate of immunocompromised mice. If the transplanted cells multiply but fail to metastasize then this will directly demonstrate the importance of the drebrin/EB3 pathway in prostate cancer cell metastasis.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. AE Dart et al., “The drebrin/EB3 pathway drives invasive activity in prostate cancer”, Oncogene, [Epub ahead of print] (2017). PMID: 28319065.
  2. RS Taichman et al., “Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone”, Cancer Res, 62, 1832–1837 (2002). PMID: 119912162.
About the Author
William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

Related Application Notes
Superior Determination of HPV using RNAscope™ In Situ Hybridization

| Contributed by Bio-Techne

Biomarker Optimization on LabSat® Research

| Contributed by Lunaphore Technologies

Diagnostics Genetics and epigenetics
A single NGS workflow for comprehensive genomic profiling

| Contributed by QIAGEN

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register